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Levodo pa- ca rbid opa has been widely used in the trea tment 
of Pa rkinson's di sease. We are currentl y inves tiga tin g the 
effectiveness of this combin ation fo r the trea tment of pa-
tient s w ith advanced mali gnant melano ma. As part of this 
study , we have exa mined the effects of this combination 
o n the phytohemagglutinin-induced transformation of hu-
man lymph ocy tes, iso lated fro m patients w ith malignant 
melano ma prior to undergoin g trea tm ent. Levodopa, as 
wel l as ca rbidopa and 3 additional Ievodopa syntheti c an-
alogs, inhibited the transfo rmation of ph ytohemagglu ti-
nin-stimul ated DNA synthes is at pharm acologica lly at-
taina ble levels. T hese results confi rm our ea rlier preclini ca l 
L evodopa- ca rbid o pa, used in the treatm cnt of Parkin-son 's di sease, is also undergoin g cl ini ca l t ri al fo r th c trea tment o f adva nced m ali gnant m elano llla , since the co mbinat ion is cytotox ic to pi g m ent produ cing ce ll s \1 -31. Preliminary evidence has shown potenti al anti-
tumo r ac ti vity in hum ans with advan ced disease 14 1. Precl inica l 
stud ies in our labo rato ry dem onstra ted that !evodopa and va rio us 
dihy d roxy analogs were also capable o f inhibi tin g the g rowth of 
leuke mi a d eri ved fro m T-cell o rigin in vitro, incl ud in g L 1210 
mu r ine, and CEM hu m an lymphocytic leuk emi as. T hese resul ts 
indicated th at it was plausible to consider that th ese dru gs might 
be capable o f affec tin g the immune system in m elano ma patients 
[5,6] . T hi s o bserv3tio n mi ght have impo rtant impli catio ns in th e 
clin ica l effects of levodo pa- ca rbid o pa sin ce the immune sys tem 
is b e lieved to pl ay an important role in the developmCll t and 
sp r ea d o f mel ano m a [7- 10]. Several studies have suggested that 
cell-mediated immunity m ay li m it the spread of thi s neo plasm 
[1 1-13'1. In te res tin g ly, an immuno logic ro le has also been impli-
ca te d in th e patho ph ys io logy of Parkin son 's di sease. Several stud-
ies h ave indi cated increased levels of herpes sim plex viral (H SV) 
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Abbrevia tions: 
3,4-DHBA: 3,4-dihydroxybenzy lamine 
H SV: hcrpes si mplex virus 
[Cso: conccntration of dru g causing 50% inhibition of 13 HITdr 
incorporation 
P HA : ph ytohemagglutinin 
T dr: th ymidine 
.observa tions sugges ting that ca techols have profound in-
trace llular metaboli c effects in a va riety of cells other than 
melano ma cell s. It is possible that some of the effects of 
ca techols in other diseases might also be mediated by sim-
ilar intracellular metabolic effects, and effects on human 
melanoma might be mediated in part through effects on 
the immune system . We are currently awaitin g introduc-
tion of syntheti c ca techols, including 3, 4-dihydroxyben-
zylamine (N SC 263475), to ex tend these observa tions to 
our clinical studies in patients with advanced m etastatic 
disease. J il-west D ermatol 88:535-537, 1987 
antibodies in sera fro l11 patients wi th this disease [1 4, 15]. Fur-
th ermo re, the level of autoa ntibodies directed against sympathetic 
neurons has been fo und to be 3 times higher in patients w ith 
Parkinso n's disease 11 61. 
This repo rt presents direct evidence that levodo pa and several 
analogs, in cl udin g ca rbido pa, ca n affec t the functi on o f the im-
mun e sys tem by meta bolic inhibi tio n o f the in v itro proliferative 
res po nse of hum an T -I ymphocy tes , derived fro m patients w ith 
m ali gnant melano m a, to phytohem agglutinin (PHA). 
MATERIALS AND M ETHODS 
Peri pheral blood was obta ined from patients w ith melanom a prio r 
to treat m ent w ith levodo pa- ca rbido pa. T he procedure was ap-
proved by th e in st itutional hum an studies review boa rd , and writ-
ten in fo rm ed consent was obta ined fro m each individual. 
Separati on o f lymphocytes fro m peripheral blood has been de-
scribed previously [1 7]. B riefl y, peripheral blood m ononuclear 
cell s were iso la ted from heparinized peripheral blood by centri f-
ugat ion ove r Ficoll- H ypaqu e. Followin g several washes , the cells 
were res uspended in m edia (Spinner 's minimal essential medium 
w ith 10% feta l calf serum, 1 % gluta mine, 100 uni ts/ml penicillin , 
and 100 /Lg/ml strepto m ycin) at 10" cells/ mL To determine the 
lym phocy ti c proliferati ve response, 3 X lOs cells w ere placed in 
wells of Fa lco n ti ssue culture trays containing 15 /Lg PHA with 
4 concentra tions of dru g. The cells were incubated at 3rC fo r 
72 h. r-'H]Td r, 2 /LC i (N ew Eng land Nuclear, Boston , M assa-
chu setts, 80 .2 C i/ mmol) w as then added to each sa mple and ex-
posed fo r 'I h . T he cells were harves ted and counted as described 
prev iously 161. 
RES ULTS 
The concentratio n o f drug res ulting in 50% inhibition of PHA-
ind uced pro liferative response (IC so) o fl ymphocytes from 10 m el-
ano m a patien ts is given in Table L T he results indicate that Je-
vodopa and its va rio us analogs con ta ining the 3, 4-dihyd roxyben-
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Table I. Effect of Dihydroxy ben zene De ri va tives o n D NA Synthes is in I) HA-Stimul ated Hum an Ly lll phocytes 
Patient 
2 3 4 5 (, 7 K 9 10 
Stimulati on In dcx" 
15 2 10 92 10 39 17 25 7 9 
Drug IC,,, (P.M) " 
Levodopa 123 141i 41) 22 180 (,Ii 128 37 7 1 GO 
Dopamine 40 103 35 93 (,3 37 36 154 94 
3,4-DHBA 28 24 21 14 (,I) 58 13 125 11 3 57 
Ca rbidopa 7(, (,8 4(, -l6 23') 11 3 26 221) 1()(J 96 
"Stimulation Index = rado of incorpOf:1tioll of IJI-I ITdr illul1sl'illllllarcd IYlll phocytcs to thl' ill co rpor:nioll of lJHITcir ill Pi-IA-stilllllbtcd cell s. 
/' IC su = the concentration o f drug ca usi ll g a SOl},;, inhi bi tioll of 1.1 11 rrell" inco rporation. 
zen e m o iety are potent inhibito rs o f ly mph ocyte rep li cation in 
the t-tM ran ge. T3ble I a lso shows tint the s timulation index , a 
measure of ly mphocyte tr3llsformation, w hich ranged from 7-2 1 D, 
has no s ig ni fica n t effect o n the inhibi to ry act iv ity of these d ru gs . 
Fig ure 1 compares the effect of 3,4-dihydroxybenzylamine (3,4-
DHBA) o n in vit ro lym phocyte proliferation usin g 2 different 
expos u re tim es. T he results us in g th e de rivat ive 3,4- D HJ3A (N SC 
263475) are illus trated s in ce it is ve ry s table und er phys io logic 
con d it io ns and is currently unde rgoin g cl ini ca l test in g. Simil a r 
res ul ts were obta ined with levodopa, dopamin e, and carbid o pa. 
T he res ults indi ca te that the inhibitory act ivity is g rea ter w hen 
the cells a re continuo us ly exposed to dru g. T hi s would sugges t 
th a t the drug is ca pable of b lock in g the blastogeni c respon se. It 
should a lso be noted th at 3 ,4-DHBA is ca pable of inhibitin g the 
proliferat ive activ ity of p res timulated ce lls, s in ce there was still 
sig nifi ca nt inhibi tion of T dr in co rpo rat io n w hen the dru g and 
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Figure 1. Effect of time of ex posure to 3,4-DHBA on DNA sy nthes is 
in PHA-stimulated hUlll an lymphocytes. Lymphocytes iso lated fro m pe-
ripheral blood of patient 9 (Table I) (D.5 x 10(' cel ls/ml) were exposed 
to PHA (15p.g). 3,4-DHI3A was added imm ediately to onc half of the 
sample (OpCII c;re/c) and thc othcr half was cx posed to the d rug after 48 h 
(ope /l sq//llre). At 48 h the cells were pulsed with 1.1 1-1 ITdr fo r 1 h :Ind th c 
amount of rad ioactivity incorporated in D N A was determ ined. The re-
sults are fro m a sin gle ex periment although the experimcnt was repeated 
3 timcs w ith simi lar results. 
labeled Tdr we re added toge ther for a I- h pulse fo ll owin g the 
48-h expos ure to PHA . Such a rapid suppress io n of DNA syn-
th esis impli es the direct inhi b it io ll of a key e ll zy m e in DNA 
rep licat io n. 
DIS C USS IO N 
T he inhibi t io n of PHA-stilllulated periphera l b lood m ononuclear 
ce ll s b y levodopa and 3,4 dihydroxy ana logs occurs at phanna-
cologica ll y re leva nt doses includin g levels that arc close to th ose 
achi eved in patients und ergoin g treatmcnt for melanoma, appar-
entl y by blocking a key step in D N A sy nthes is 11 8, 19]. T hese 
obse rvati o ns suppo rt the contentio n that these dru gs arc p o ten-
tially c:t pable of affec tin g the immune systcm. Alth o u g h the exact 
exten t of thi s effect is unclca r , a study by Kirtland et al [20] 
showed th at the antihypertensive drug a-methy ldopa h as no di-
rec t effect o n B ce ll s, but ca n affect antibody productio n by a 
selective inhibitio n of T - ly mphocyte transformation. It would 
appear that levodopa-ca rbid o pa may ha ve the sa m e selecti ve effect 
o n the immune system as m eth y ld o pa, since all of these drugs 
possess the o rth o -dih yd roxybenzene m o iety that is the active 
stru ctura l feature rcquired for inhibiting T-Iy mphocyte prolif-
eratio n . T hc extensive biochc mi ca l pharmacology of the ca tcchols 
that has been described by o ur laboratory mi g ht be relevant to 
an cxplanatio n of the a-methy ldopa phenomenon. 
O ur pre liminary resu lts do not show a co rrel atio n between 
res po nsiveness to inhibiti o n b y levod opa-carbidopa and clinical 
antitumo r response, but the patient sa mpJc was limited. In ad-
ditio n to stud y in g the relat io nship o f ly mph ocyte inhibitio n to 
antitum o r response, we arc act ively stud y ill g the effects of le-
vodopa-carbidopa o n ly mph ocyte subset pop ulati o ns as well as 
the ability to suppress ly mphocyte transfo rm atio n in v ivo. 
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